Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price ...

New prescriptions for these drugs have doubled among people who have obesity but not diabetes ... semaglutide for use as a ...

Other analysts are more cautious, however, predicting peaks sales of $1 billion or lower and pointing to lacklustre take-up of other new obesity drugs such as Eisai and Arena's Belviq (lorcaserin ...

Researchers at Karolinska Institutet may have found a new way to treat ... that a specific class of drugs that block ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

Beyond obesity, potential indications for these drugs include sleep apnea, addiction, Alzheimer’s disease, and metabolic dysfunction-associated steatohepatitis (MASH). New medications for these ...

Previously, she was executive editor of Chemical & Engineering News. In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans with Medicare and Medicaid, according to the White House.

New guidelines are changing how obesity is diagnosed. One change is establishing a “pre-clinical” category, which could help with providing coverage for medications and surgical procedures ...